Brevan Howard Capital Management LP purchased a new position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,636 shares of the health services provider's stock, valued at approximately $239,000.
Several other hedge funds have also recently added to or reduced their stakes in AMED. Barclays PLC lifted its stake in Amedisys by 49.5% during the third quarter. Barclays PLC now owns 15,529 shares of the health services provider's stock worth $1,500,000 after purchasing an additional 5,142 shares during the last quarter. HBW Advisory Services LLC bought a new stake in shares of Amedisys in the 4th quarter valued at about $38,000. Oak Thistle LLC lifted its stake in shares of Amedisys by 97.6% in the 4th quarter. Oak Thistle LLC now owns 6,964 shares of the health services provider's stock valued at $632,000 after acquiring an additional 3,440 shares during the last quarter. Ballentine Partners LLC bought a new stake in shares of Amedisys in the 4th quarter valued at about $334,000. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Amedisys by 1.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 15,150 shares of the health services provider's stock valued at $1,375,000 after acquiring an additional 180 shares during the last quarter. Institutional investors own 94.36% of the company's stock.
Amedisys Trading Up 1.0%
AMED traded up $0.90 during midday trading on Friday, reaching $94.62. 440,407 shares of the company's stock traded hands, compared to its average volume of 420,849. The firm has a fifty day moving average of $93.22 and a two-hundred day moving average of $91.63. The stock has a market capitalization of $3.11 billion, a price-to-earnings ratio of 37.55, a P/E/G ratio of 1.78 and a beta of 0.96. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95.
Amedisys (NASDAQ:AMED - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. During the same quarter in the prior year, the business earned $1.03 EPS. The business's revenue for the quarter was up 4.1% on a year-over-year basis. On average, equities analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.
Analysts Set New Price Targets
AMED has been the subject of a number of recent research reports. Stephens reissued an "equal weight" rating and issued a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 target price on shares of Amedisys in a research note on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $100.75.
Get Our Latest Research Report on Amedisys
Amedisys Company Profile
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Read More
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
